BTIG Research Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating restated by research analysts at BTIG Research in a report released on Tuesday, Benzinga reports. They presently have a $2.00 price target on the stock. BTIG Research‘s target price points to a potential upside of 334.78% from the company’s current price.

HUMA has been the subject of several other research reports. Benchmark cut their price objective on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a report on Thursday, August 13th. Williams Trading set a $1.00 target price on Humacyte in a research report on Friday, October 16th. Wall Street Zen cut shares of Humacyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Barclays upgraded Humacyte to a “hold” rating in a research report on Wednesday, October 7th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Humacyte in a research note on Friday, October 16th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $4.96.

Humacyte Stock Up 2.6%

HUMA opened at $0.46 on Tuesday. The company has a debt-to-equity ratio of 2.07, a current ratio of 6.21 and a quick ratio of 5.74. Humacyte has a fifty-two week low of $0.34 and a fifty-two week high of $1.52. The company’s 50-day moving average is $0.49 and its 200 day moving average is $0.79.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.04. Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%. The company had revenue of $1.03 million during the quarter, compared to analyst estimates of $0.77 million. As a group, research analysts anticipate that Humacyte will post -0.40 EPS for the current fiscal year.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently modified their holdings of the company. Alyeska Investment Group L.P. purchased a new stake in shares of Humacyte during the second quarter worth approximately $4,700,000. BlackRock Inc. purchased a new position in Humacyte during the 2nd quarter worth approximately $3,777,000. GSA Capital Partners LLP acquired a new stake in Humacyte during the 2nd quarter worth $785,000. HBK Investments L P purchased a new position in shares of Humacyte in the 2nd quarter valued at approximately $617,000. Finally, Wealth Effects LLC purchased a new position in Humacyte in the second quarter worth $542,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient.

Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.